Heidi Greulich

37.9k citations

52 papers · 15.1k indexed · 5 hit papers · h-index 31

Impact in

Oncology top 0.1%
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
Pulmonary and Respiratory Medicine top 0.05%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment

Papers in

Oncology 24
- HER2/EGFR in Cancer Research 16
Pulmonary and Respiratory Medicine 27
- Lung Cancer Treatments and Mutations 24

Co-authors: Matthew Meyerson Michael J. Eck William R. Sellers Titus J. Boggon Pasi A. Jänne Bruce E. Johnson Jeffrey C. Lee Stacey Gabriel
Journals: Cancer Research (13 papers)Journal of Biological Chemistry (4 papers)Cancer Cell (3 papers)Journal of Clinical Oncology (3 papers)Molecular Cancer Therapeutics (2 papers)
Partner nations: United States Germany Netherlands

In The Last Decade

Heidi Greulich

48 papers receiving 14.7k citations

Hit Papers

5 papers align trajectories log scale

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP 2008 · 1.6k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2008 Proceedings of the National Academy of Sciences
2008 Oncogene
2007 Cancer Cell
2005 PLoS Medicine
2004 Science

Peers

Countries citing papers authored by Heidi Greulich

Since Specialization

Citations

This map shows the geographic impact of Heidi Greulich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heidi Greulich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heidi Greulich more than expected).

Fields of papers citing papers by Heidi Greulich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heidi Greulich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heidi Greulich. The network helps show where Heidi Greulich may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Heidi Greulich, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Heidi Greulich Line = papers co-authored together Heidi Greulich links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Abstract A037: Mechanisms of resistance to BAY 2927088, the first reversible inhibitor targeting EGFR exon 20 insertion mutations in non-small cell lung cancer Molecular Cancer Therapeutics ·Antoine Rozès, Kayleen P. Walsh, E Asiedu Darko, T Nagai, Д С Мартьянов, Hasmik Keshishian, Steven A. Carr, Xiaoping Yang, David E. Root, Andrew D. Cherniack, Franziska Siegel, Stephan Siegel, Matthew Meyerson, Heidi Greulich	2023	0
2	Velcrin-induced selective cleavage of tRNALeu(TAA) by SLFN12 causes cancer cell death Nature Chemical Biology ·Sooncheol Lee, Md Mofasserul Alam, Xiaoyun Wu, Colin W. Garvie, H. Holweger, Mrinal Shekhar, Marcus Tötzl, Matthew G. Rees, Andrew D. Cherniack, Matthew Meyerson, Heidi Greulich	2022	25
3	Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12 Journal of Biological Chemistry ·Xiaoyun Wu, Gavin R. Schnitzler, Galen F. Gao, Y Liu, Andrew R. Baker, Bethany Kaplan, Kaylyn E. Williamson, Lindsay Westlake, Selena Lorrey, Timothy A. Lewis, Colin W. Garvie, Martin Lange, Sikander Hayat, Henrik Seidel, John G. Doench, Andrew D. Cherniack, Charlotte Kopitz, Matthew Meyerson, Heidi Greulich	2020	18
4	Cetuximab Response of Lung Cancer–Derived EGF Receptor Mutants Is Associated with Asymmetric Dimerization Cancer Research ·Jeonghee Cho, Liang Chen, Naveen F. Sangji, Takafumi Okabe, Kimio Yonesaka, Joshua M. Francis, Richard Flavin, Tamara H. Banty, Jihyun Kwon, Soyoung Yu, Heidi Greulich, Bruce E. Johnson, Michael J. Eck, Pasi A. Jänne, Kwok‐Kin Wong, Matthew Meyerson	2013	86
5	Abstract 2: FGFR3 as a therapeutic target in squamous cell lung carcinoma Cancer Research ·Rachel G. Liao, Peter S. Hammerman, Andrey Sivachenko, Heidi Greulich, Gad Getz, Qingsong Liu, Nathanael S. Gray, Matthew Meyerson	2012	7
6	Targeting mutant fibroblast growth factor receptors in cancer Trends in Molecular Medicine ·Heidi Greulich, Pamela M. Pollock	2011	6
7	Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation Cancer Research ·Martin L. Sos, Haridas B. Rode, Stefanie Heynck, Martin Peifer, Florian Fischer, Sabine Klüter, Claudia P. Cartaya Marin, Katherine Nguyen, Johannes M. Heuckmann, Jonathan M. Weiss, Lars Ruddigkeit, Matthias Rabiller, Mirjam Koker, Jeffrey R. Simard, Matthäus Getlik, Yuki Yuza, Tzu-Hsiu Chen, Heidi Greulich, Roman K. Thomas, Daniel Rauh	2010	175
8	An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells Cancer Cell ·Qing Sheng, Xinggang Liu, Eleanor Fleming, Karen Yuan, Huiying Piao, Jinyun Chen, J. Roche, Roman K. Thomas, Heidi Greulich, Anna C. Schinzel, Sara Zaghlul, David Batt, Seth A. Ettenberg, Matthew Meyerson, Birgit Schoeberl, Andrew L. Kung, William C. Hahn, Ronny Drapkin, David M. Livingston, Joyce F. Liu	2010	178
9	An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells Cancer Cell ·Quan Z. Sheng, Xinggang Liu, Jay A. Levenson, Karen Yuan, Huiying Piao, Jinyun Chen, J. Roche, Roman K. Thomas, Heidi Greulich, Anna C. Schinzel, Sara Zaghlul, David Batt, Seth A. Ettenberg, Matthew Meyerson, Andrew L. Kung, William C. Hahn, Ronny Drapkin, David M. Livingston, Joyce F. Liu	2010	10
10	The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Proceedings of the National Academy of Sciences ·Cai‐Hong Yun, Kristen E. Mengwasser, Angela V. Toms, Michele Sue‐Ann Woo, Heidi Greulich, Kwok‐Kin Wong, Matthew Meyerson, Michael J. Eck Hit paper breakdown →	2008	1564
11	Inhibition of Hsp90 Down-regulates Mutant Epidermal Growth Factor Receptor (EGFR) Expression and Sensitizes EGFR Mutant Tumors to Paclitaxel Cancer Research ·Ayana Sawai, Sarat Chandarlapaty, Heidi Greulich, Mithat Gönen, Qing Ye, Carlos L. Arteaga, William R. Sellers, Neal Rosen, David B. Solit	2008	145
12	Modeling Genomic Diversity and Tumor Dependency in Malignant Melanoma Cancer Research ·William M. Lin, Alissa C. Baker, Rameen Beroukhim, Wendy Winckler, Whei Feng, Mathan Siegrist, Elisabeth Laine, Heidi Greulich, Hsiuyi Tseng, Casey Gates, F. Stephen Hodi, Glenn Dranoff, William R. Sellers, Roman K. Thomas, Matthew Meyerson, Todd R. Golub, Reinhard Dummer, Meenhard Herlyn, Gad Getz, Levi A. Garraway	2008	215
13	SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines Nucleic Acids Research ·Francesca Demichelis, Heidi Greulich, Jill A. Macoska, Rameen Beroukhim, William R. Sellers, Levi A. Garraway, Mark A. Rubin	2008	49
14	The kinesin KIF1Bβ acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor Genes & Development ·Susanne Schlisio, Rajappa S. Kenchappa, Liesbeth C.W. Vredeveld, Rani E. George, Rodney A. Stewart, Heidi Greulich, Kristina Shahriari, Tarquinio (1573?-1649). Auteur du texte Galluzzi, Pascal Pigny, Patricia L. M. Dahia, Scott L. Pomeroy, John M. Maris, A. Thomas Look, Matthew Meyerson, Daniel S. Peeper, Bruce Carter, William G. Kaelin	2008	257
15	C7-04: Efficacy of BIBW 2992, a potent irreversible inhibitor of EGFR and HER2 in human NSCLC xenografts and in a transgenic mouse lung-cancer model Journal of Thoracic Oncology ·Takeshi Shimamura, Heidi Greulich, Flavio Solca, Kwok‐Kin Wong	2007	8
16	Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity Cancer Cell ·Cai‐Hong Yun, Titus J. Boggon, Yiqun Li, Michele Sue‐Ann Woo, Heidi Greulich, Matthew Meyerson, Michael J. Eck Hit paper breakdown →	2007	904
17	Signal Transducer and Activator of Transcription 3 Is Required for the Oncogenic Effects of Non–Small-Cell Lung Cancer–Associated Mutations of the Epidermal Growth Factor Receptor Cancer Research ·James V. Alvarez, Heidi Greulich, William R. Sellers, Matthew Meyerson, David A. Frank	2006	206
18	Detection of Oncogenic Mutations in the EGFR Gene in Lung Adenocarcinoma with Differential Sensitivity to EGFR Tyrosine Kinase Inhibitors Cold Spring Harbor Symposia on Quantitative Biology ·Reji Koshy Thomas, Heidi Greulich, V. Krauthamer, Janice Lee, Torstein Tengs, William W. Feng, Tao‐Hsing Chen, Elizabeth Nickerson, A. Feldmeier-Krause, Michael D. Miller, Jonathan M. Rothberg, William R. Sellers, Matthew Meyerson	2005	27
19	Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants PLoS Medicine ·Heidi Greulich, Tzu-Hsiu Chen, Whei Feng, Pasi A. Jänne, James V. Alvarez, Taís da Silva Dias, 陽一郎柏木, David A. Frank, William C. Hahn, William R. Sellers, Matthew Meyerson Hit paper breakdown →	2005	536
20	EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy Science ·J. Guillermo Paez, Pasi A. Jänne, Jeffrey C. Lee, Sean Tracy, Heidi Greulich, Stacey Gabriel, Paula Herman, Frederic J. Kaye, Neal I. Lindeman, Titus J. Boggon, Katsuhiko Naoki, Hidefumi Sasaki, Yoshitaka Fujii, Michael J. Eck, William R. Sellers, Bruce E. Johnson, Matthew Meyerson Hit paper breakdown →	2004	7539

About Heidi Greulich

Heidi Greulich is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 52 papers that have together received 15.1k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (24 papers), HER2/EGFR in Cancer Research (16 papers), Cancer therapeutics and mechanisms (9 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), PI3K/AKT/mTOR signaling in cancer (4 papers), Fibroblast Growth Factor Research (3 papers), Melanoma and MAPK Pathways (3 papers) and Cancer Genomics and Diagnostics (3 papers). The work is most often cited by research in Oncology (8.6k citations), Pulmonary and Respiratory Medicine (9.0k citations), Cancer Research (3.1k citations), Molecular Biology (7.5k citations) and Genetics (870 citations). Heidi Greulich has collaborated with scholars based in United States, Germany and Netherlands. Frequent co-authors include Matthew Meyerson, Michael J. Eck, William R. Sellers, Titus J. Boggon, Pasi A. Jänne, Bruce E. Johnson, Jeffrey C. Lee, Stacey Gabriel, Neal I. Lindeman and Katsuhiko Naoki. Their work appears in journals such as Cancer Research, Journal of Biological Chemistry, Cancer Cell, Journal of Clinical Oncology and Molecular Cancer Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact